Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Universitätsmedizin Mannheim
With
Klinikum Minden
Helios Klinikum Krefeld
Wuerzburg University Hospital
KKS Netzwerk
Klinikum Ludwigshafen
University of Kiel
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histopathologically confirmed Mycosis fungoides or Sézary syndrome (CTCL stage ≥ Ib according to EORTC-ISCL consensus classification) at study entry with progressive, persistant or recurrent disease
Pretreatment with at least one topical or systemic CTCL therapy or UV therapy, if the prior therapy is not possible anymore or if there is new contraindication or unsatisfactory response
Karnofsky index ≥70 % (according to Karnofsky DA, Burchenal JH. (1949). "The Clinical Evaluation of Chemotherapeutic Agents in Cancer." In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press. Page 196)
Negative Pregnancy test from blood, agreement for efficient contraception in male and female patients unless infertility is documented (DMF is not approved during pregnancy)
Ability to understand character and individual consequences of the clinical trial and to provide written informed consent to participate in the study
written informed consent must be given according to ICH/GCP, and national/local regulations, before patient registration and prior to any study specific procedures.
You may not be if
Another active malignant disease with the following exceptions:
Basal or squamous cell carcinoma of the skin
In situ carcinoma of the cervix or the skin
Topical chemotherapy, superficial radiotherapy, photopheresis or systemic CTCL treatment within 28 days before study therapy initiation
Severe systemic disease or infection at study therapy initiation
Prior treatment with DMF or simultaneous topical DMF treatment
Contraindications for treatment with DMF (known hypersensibility to the drug, severe gastrointestinal disease (like ulcerations), Alcohol abuse, other obligately liver- or nephrotoxic medication, known clinically apparent renal or hepatic insufficiency)
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Participation in other clinical studies within 14 days before study therapy initiation